"FDA Approves Merck's Breakthrough Drug for Rare, Fatal Conditions"
The FDA has approved a new drug called sotatercept, now known as Winrevair, for the treatment of pulmonary arterial hypertension (PAH), a rare and fatal condition. The drug, manufactured by Merck, has shown promising results in clinical trials, with patients experiencing improved ability to walk and reduced risk of disease progression. While the drug has shown potential for reversing the effects of PAH, there are still unknowns and potential side effects, including bleeding and dizziness. The annual cost of the medication is estimated to be around $243,000, and it will be available in specialty pharmacies by the end of April. Patients initially need to receive injections in a clinic but may eventually be able to administer the drug at home.